Turnstone biologics corp. reports second quarter 2023 financial results and provides business update

San diego, sept. 01, 2023 (globe newswire) -- turnstone biologics corp. (“turnstone” or the “company”) (nasdaq: tsbx), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (til) therapy, today announced financial results for the second quarter ended june 30, 2023, and provided an update on recent business highlights.
TSBX Ratings Summary
TSBX Quant Ranking